Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immune Response Persistence After One Dose of 9vHPV Vaccine
NCT07156084Phase 4Recruiting
- Sponsor
- Canadian Immunization Research Network
- Start
- Sep 2025
- Primary completion
- Feb 2026
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 4 trial of recombinant human papillomavirus 9-valent vaccine in human papillomavirus infection, sponsored by Canadian Immunization Research Network. Started Sep 2025; status: recruiting.
02
Drugs
recombinant human papillomavirus 9-valent vaccine
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on NCT07156084.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07156084.